| Biomarker ID | 1323 |
| PMID | 24477576 |
| Year | 2014 |
| Biomarker | miR-101 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include: DNA binding; Gene expression (Transcription); Generic Transcription Pathway; RNA Polymerase II Transcription; DNA-binding transcription factor activity, RNA polymerase II-specific |
| Experiment | African Americans Vs Caucasian Americans with PCa |
| Type of Biomarker | Diagnostic |
| Cohort | 40 PCa patients (16 Caucasian American) and (24 African Americans) along with 32 controls (20 Caucasian American) and (12 African Americans) were selected for analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.80 (95% CI: 0.69-0.90) |
| Accuracy | NA |
| Level Of Significance | p= 0.0006 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Also significantly downregulated when only Caucasian American population is considered alone |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | miR-101 |